Clinical Trial

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

Name: A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — clinical trial record (NCT07599813)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-05-15.

Trial Details

NCT Number	NCT07599813
Lead Sponsor	Apollo Therapeutics Ltd
Conditions	Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Enrollment	280 participants
Start Date	2026-05-28
Primary Completion	2027-10-31 (estimated)
Study Completion	2028-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-12